US Food and Drug Administration Commissioner Marty Makary is resigning after 13 months in the role, according to President Donald Trump, marking another leadership shakeup across federal health agencies. Kyle Diamantas, the FDA’s former top food official, is expected to serve as acting commissioner as the administration weighs additional personnel changes at the agency.
- Trump said Makary “was having some difficulty” while announcing the departure Tuesday at the White House.
- Makary’s tenure included high turnover, disputes with industry groups, and internal personnel clashes at the FDA.
- The S&P 500 Biotechnology Index rose 2.4% following news of the resignation.
- The FDA is currently overseeing issues including synthetic food dye regulation, drug advertising policy, and a hantavirus outbreak response.
- Diamantas previously worked at Jones Day advising food and beverage industry clients before joining the FDA.
Relevant Companies
- Amgen ($AMGN) - FDA leadership changes could affect drug review timelines and regulatory policy.
- Moderna ($MRNA) - Biotech companies remain sensitive to FDA oversight and approval processes.
- Coca-Cola ($KO) - Food additive and synthetic dye regulations remain a focus under HHS and FDA leadership.
Editor’s Note: This is a developing story. This article may be updated as more details become available.
